Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

'Pivotal Topline Up Next' for Biotech's Phase 3 Cardiac Clinical Trial

A study update and the next steps to advance the therapeutic were covered in a ROTH Capital Partners report. In an April 25 research note, ROTH Capital Partners analyst Jotin Marango reported that the last required major adverse cardiac event, the 250th, occ...
Streetwise Reports | May 2, 2019 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

Revolutionizing vascular grafting with a durable solution

Our next guest is a multi-technology biomedical company, focused on the development and commercialization of medical technologies. Marizyme Inc. (OTCQB:MRZM) has had its sights set on development of medical technology and products, one of which is DuraGraft. J...
Brieanna McCutcheon | September 27, 2023 |

Medtronic Stock Hits All-Time High After Raising 2020 EPS Outlook

Dublin-based Medtronic reported Q1/20 earnings and revised its full-year earnings outlook upward sending shares up more than 5% today. Medical device developer and manufacturer Medtronic Inc. (MDT:NYSE) today announced financial results for its first quarter of fi...
Streetwise Reports | August 22, 2019 |

Zynex Shares Trade Higher After Reporting a 95% Increase in Q3 Orders

Non-invasive medical device maker Zynex Inc's. shares are trading 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018. This morning medical technology company specializing in manufacturing and s...
Streetwise Reports | October 3, 2019 |

CytoSorbents Shares Trade 20% Higher as FDA Grants CytoSorb EUA for COVID-19

Shares of CytoSorbents traded higher setting a new 52-week intraday high price after the company reported that the FDA granted emergency use authorization for CytoSorb for use in patients with COVID-19. Critical care immunotherapy company CytoSorbents Corp....
Streetwise Reports | April 14, 2020 |

Improved Recovery Rate Spurs Target Price Increase on Gold Developer

The metallurgical result and its implications are addressed in a ROTH Capital Partners report. In an Aug. 14 research note, ROTH Capital Partners analyst Jake Sekelsy reported that the final results from the metallurgical work done at Vista Gold Corp.'s (VGZ:...
Streetwise Reports | August 20, 2019 |

Analyst: Valero Energy's Q3/19 Numbers Trimmed, Q4/19 Outlook Improved

In a research report, Raymond James revisits and revises its Q3/19 projections on this company. In an Oct. 1 note, Raymond James analyst Justin Jenkins reported that Valero Energy Corp.'s (VLO:NYSE) adherence to a disciplined strategy continues to drive strong perfo...
Streetwise Reports | October 4, 2019 |

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'

The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. Beaker In a May 20 research report, ROTH Capital Partners analyst Yasmeen Rahimi reported that The Medicines Company's (MDCO:...
Streetwise Reports | May 30, 2019 |

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report

Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. Structural heart disease and critical care monitor...
Streetwise Reports | July 25, 2019 |
1 2 3 4 5 6 7 8 9 10 ...